Abstract
Δ 9-tetrahydrocannabinol (Δ 9-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to be devoid of pharmacological activity. However, laboratory rodents and human studies have shown that this cannabinoid is able to prevent psychotic-like symptoms induced by high doses of Δ 9- THC. Subsequent studies have demonstrated that CBD has antipsychotic effects as observed using animal models and in healthy volunteers. Thus, this article provides a critical review of the research evaluating antipsychotic potential of this cannabinoid. CBD appears to have pharmacological profile similar to that of atypical antipsychotic drugs as seem using behavioral and neurochemical techniques in animal models. Additionally, CBD prevented human experimental psychosis and was effective in open case reports and clinical trials in patients with schizophrenia with a remarkable safety profile. Moreover, fMRI results strongly suggest that the antipsychotic effects of CBD in relation to the psychotomimetic effects of Δ 9-THC involve the striatum and temporal cortex that have been traditionally associated with psychosis. Although the mechanisms of the antipsychotic properties are still not fully understood, we propose a hypothesis that could have a heuristic value to inspire new studies. These results support the idea that CBD may be a future therapeutic option in psychosis, in general and in schizophrenia, in particular.
Keywords: Cannabidiol, CBD, cannabis, antipsychotic, psychosis
Current Pharmaceutical Design
Title:A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation
Volume: 18 Issue: 32
Author(s): Antonio Waldo Zuardi, Jose Alexandre S. Crippa, Jaime E.C. Hallak, Sagnik Bhattacharyya, Zerrin Atakan, Rocio Martin-Santos, Philip K. McGuire and Francisco Silveira Guimaraes
Affiliation:
Keywords: Cannabidiol, CBD, cannabis, antipsychotic, psychosis
Abstract: Δ 9-tetrahydrocannabinol (Δ 9-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to be devoid of pharmacological activity. However, laboratory rodents and human studies have shown that this cannabinoid is able to prevent psychotic-like symptoms induced by high doses of Δ 9- THC. Subsequent studies have demonstrated that CBD has antipsychotic effects as observed using animal models and in healthy volunteers. Thus, this article provides a critical review of the research evaluating antipsychotic potential of this cannabinoid. CBD appears to have pharmacological profile similar to that of atypical antipsychotic drugs as seem using behavioral and neurochemical techniques in animal models. Additionally, CBD prevented human experimental psychosis and was effective in open case reports and clinical trials in patients with schizophrenia with a remarkable safety profile. Moreover, fMRI results strongly suggest that the antipsychotic effects of CBD in relation to the psychotomimetic effects of Δ 9-THC involve the striatum and temporal cortex that have been traditionally associated with psychosis. Although the mechanisms of the antipsychotic properties are still not fully understood, we propose a hypothesis that could have a heuristic value to inspire new studies. These results support the idea that CBD may be a future therapeutic option in psychosis, in general and in schizophrenia, in particular.
Export Options
About this article
Cite this article as:
Waldo Zuardi Antonio, Alexandre S. Crippa Jose, E.C. Hallak Jaime, Bhattacharyya Sagnik, Atakan Zerrin, Martin-Santos Rocio, K. McGuire Philip and Silveira Guimaraes Francisco, A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884681
DOI https://dx.doi.org/10.2174/138161212802884681 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Food-derived bioactive peptides against chronic diseases
Chronic diseases, such as cardiovascular diseases and metabolic diseases, have become a great threat to the human health in recent decades due to the excessive food consumption and the prevalence of sedentary lifestyle. As a class of natural compounds, food-derived bioactive peptides have been demonstrated to possess great potential for ...read more
Innovative delivery systems and formulations for the management of diseases affecting the skin and skin appendages
Skin and skin appendage diseases have high incidence and can highly impact the quality of life. Such diseases include pigmentation disorders, such as melasma, vitiligo and post-inflammatory hyperpigmentation, infectious diseases caused by fungi, viruses, bacteria and parasites, inflammatory diseases such as acne, dermatitis, rosacea, and psoriasis, as well as skin ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Electrochemistry of Alzheimer Disease Amyloid Beta Peptides
Current Medicinal Chemistry Metabolic Syndrome, Mild Cognitive Impairment and Dementia
Current Alzheimer Research Recent Developments on the Studies of Human Memapsin 2 (β-Secretase)
Current Alzheimer Research Editorial:Genomics and Epigenomics of Tumor and Aging Cells
Current Genomics The Endocannabinoid System May Modulate Sleep Disorders in Aging
Current Neuropharmacology Exploring New Vista for Alzheimer's Disease Drug Targets (Part II)
Current Topics in Medicinal Chemistry GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients
Current Hypertension Reviews Cellular Reservoirs of HIV-1 and their Role in Viral Persistence
Current HIV Research Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments
Current Drug Targets Automatic Detection of Cognitive Impairments through Acoustic Analysis of Speech
Current Alzheimer Research Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine Modulation of Transient Receptor Potential Vanilloid Subtype 1 (TRPV<sub>1</sub>) and Norepinephrine Transporters (NET) Protect Against Oxidative Stress, Cellular Injury, and Vascular Dementia
Current Neurovascular Research Estrogen Deprivation and Myocardial Infarction: Role of Aerobic Exercise Training, Inflammation and Metabolomics
Current Cardiology Reviews Conference Report: 8<sup>th</sup> Clinical Trials on Alzheimer Disease (CTAD), Barcelona, Spain November 5-7, 2015
CNS & Neurological Disorders - Drug Targets Amyloid β Accumulation Assessed with <sup>11</sup>C-Pittsburgh Compound B PET and Postmortem Neuropathology
Current Alzheimer Research Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease
Current Pharmaceutical Design Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Hot Topic: Coming Back to Nature: Plants as a Vital Source of Pharmaceutically Important Metabolites – Part II B)
Current Medicinal Chemistry Exerkines: A Crosstalk between Lactate Production, Exercise and Mental Health
CNS & Neurological Disorders - Drug Targets